Potential strategies against resistance to CAR T-cell therapy in haematological malignancies.
Qing CaiMingzhi ZhangZhaoming LiPublished in: Therapeutic advances in medical oncology (2020)
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly developing method for adoptive immunotherapy of tumours in recent years. CAR T-cell therapies have demonstrated unprecedented efficacy in the treatment of patients with haematological malignancies. A 90% complete response (CR) rate has been reported in patients with advanced relapse or refractory acute lymphoblastic leukaemia, while >50% CR rates have been reported in cases of chronic lymphocytic leukaemia and partial B-cell lymphoma. Despite the high CR rates, a subset of the patients with complete remission still relapse. The mechanism of development of resistance is not clearly understood. Some patients have been reported to demonstrate antigen-positive relapse, whereas others show antigen-negative relapses. Patients who relapse following CAR T-cell therapy, have very poor prognosis and novel approaches to overcome resistance are required urgently. Herein, we have reviewed current literature and research that have investigated the strategies to overcome resistance to CAR T-cell therapy.
Keyphrases
- cell therapy
- poor prognosis
- stem cells
- mesenchymal stem cells
- free survival
- long non coding rna
- newly diagnosed
- systematic review
- ejection fraction
- end stage renal disease
- liver failure
- high resolution
- prognostic factors
- atomic force microscopy
- acute respiratory distress syndrome
- risk assessment
- climate change
- intensive care unit
- single molecule
- hepatitis b virus
- respiratory failure
- ulcerative colitis